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ABSTRACT  
 
Background:  We tested the hypotheses that caffeine therapy would increase the 
ventilatory response to hypercarbia in infants above the effect of maturation and those 
with a weaker ventilatory response to hypercarbia would be more likely to 
subsequently develop apnoea which required treatment. 
 
Methods: Infants born less than 34 weeks of gestation underwent a steady state 
hypercarbic challenge using 0%, 2% and 4% carbon dioxide soon after birth which 
was repeated at weekly intervals. The results of the initial study were compared 
between infants who did or did not subsequently develop apnoea requiring treatment 
with caffeine.  
 
Results: Twenty-six infants born at a median gestation of 32 (range 31-33) weeks 
were assessed.  Caffeine administration was associated with an increase in CO2 
sensitivity, the mean increase was 15.3; (95% CI: 1-30) ml/kg/min/%CO2. Fourteen 
infants subsequently developed apnoea treated with caffeine. After controlling for 
gestational age and birth weight, they had significantly lower carbon dioxide 
sensitivity at their initial study compared to those who did not require treatment.  
 
Conclusions: Caffeine administration was associated with an increase in the 
ventilatory response to hypercarbia. An initial weaker ventilatory response to 
hypercarbia was associated with the subsequent development of apnoea requiring 
treatment with caffeine. 
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INTRODUCTION 
 
Apnoea of prematurity is a common problem in prematurely born infants (1) 
occurring most often in those born very prematurely (2).  It is possible that a reduced 
chemoresponse to hypercarbia may contribute to the development of apnoea (1).  
Indeed, at approximately one week of age, 18 infants with significant apnoea (a mean 
of 32 apnoeas lasting longer than 20 seconds per day) had a reduced ventilatory 
response to carbon dioxide (CO2) compared to 18 matched controls without apnoea 
(3). 
 
Caffeine, a methylxanthine, reduces the frequency of apnoeas in preterm infants (4).  
It increases the ventilatory response to hypercarbia in animals (5) and adults (6, 7). In 
anaesthetised cats, caffeine administration resulted in an increase in minute 
ventilation, as well as an increased ventilatory response to inspired CO2 (5). 
Administration of theophylline, another methylxanthine, to ten infants with a median 
gestational age of 30 weeks and apnoea was associated with an increase in minute 
volume in response to breathing 3% CO2 and lower end-tidal CO2 levels (8).  The 
measurements, however, were made prior to and between two and four days after 
administration of theophylline and no attempt was made to determine whether the 
effects were due to maturation rather than theophylline administration per se (8). No 
study has investigated whether caffeine administration influences the ventilatory 
response to hypercarbia of prematurely born infants.  We hypothesised that the 
ventilatory response to hypercarbia would be increased following administration of 
caffeine and any effect would be additional to the effect of increasing maturation.  
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Furthermore, we postulated that those infants who went on to require treatment with 
caffeine compared to those that did not would, when first studied, have a lower 
response to a CO2 challenge.   We have undertaken a longitudinal study to test those 
hypotheses 
 
 
METHODS 
 
The study was performed at King’s College Hospital NHS Foundation Trust between 
May 2013 and August 2015. Infants were eligible for entry into the study if they were 
born at less than 34 weeks of gestation, did not require respiratory support and were 
less than 72 hours of age.  Infants were only entered into the study if they had not 
received caffeine.  Infants with major congenital abnormalities were excluded from 
the study. A hypercapnic challenge was undertaken and repeated at weekly intervals 
until the infants were discharged from the neonatal unit.  Infants who developed 
clinically significant apnoea (see later) during the course of the study were treated 
with caffeine.  Parent(s) gave informed, written consent for their infant to take part in 
the study, which was approved by the London Bromley Research Ethics Committee.  
 
The hypercapnic challenge 
The test gas was delivered using an open circuit system via a nasal mask and 
pneumotachograph. The pneumotachograph (Mercury F10L, G M Instruments, 
Kilwinning, Scotland) which had a dead space 0.8 ml and resistance 0.86 
mmH2O/L/min, was connected to a soft latex nasal mask (Neomask, Draeger, 
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Germany) using a snugly fitting connector. The pneumotachograph was connected to 
a differential pressure transducer-amplifier system (Gould model 13-4615-70, 
Cleveland OH) generating an analogue signal proportional to airflow.  The mask was 
placed over the infant’s nose. A nasal mask (deadspace 7.5 mls) was used to avoid the 
stimulation that can result if a facemask is used (9). A seal was achieved by gentle 
pressure and confirmed by demonstration of no leak (there was no discrepancy 
between the inspired and expired tidal volumes as displayed in real time on the 
computer screen.  We monitored the flow waveforms to ensure no airway obstruction 
was occurring.  The distal end of the pneumotachograph was connected to a two-way 
non-rebreathing valve which separated inspired from expired gas, such that the 
controlled mixture of gases was inspired by the infant and expiration was to the 
outside air. A constant flow of medical air was delivered to the inspiratory port of the 
valve via wide bore (20 mm), low resistance tubing to eliminate any dead space. The 
inspired air could be enriched with a variable concentration of CO2 from a cylinder. 
Gas was continuously sampled from the nasal mask through a fine bore catheter at a 
rate of 180ml/minute using a capnograph (CO2SMO capnograph; (Respironics UK, 
Chichester, UK). The CO2 content of the sampled gas was determined by infrared 
spectroscopy and an analogue signal proportional to the CO2 concentration generated. 
Oxygen saturation was measured using a pulse oximeter (Masimo rainbow SET Pulse 
Oximetry) attached to the foot of the infant. 
 
Following a five minute period of breathing medical air, the hypercarbic challenge 
was delivered through the equipment described above. CO2 was delivered from a 
cylinder of CO2 20% balanced with medical air (BOC), via a low-flow meter.  Minute 
volume was measured during exposure to three levels of CO2 (0% (baseline), 2% and 
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4%). Those levels were chosen as they have been previously demonstrated to result in 
changes in respiration without significant behavioural arousal (10-13). Each mixture 
of CO2 was titrated using a low flow flowmeter attached to the CO2 regulator.  The 
capnograph read out was used to determine when a stable inspiratory CO2 
concentration within the delivery tubing had been achieved.  
 
The fraction of inspired oxygen was not monitored or controlled, however, addition of 
a maximum of 4% CO2 would result in a potential reduction in the inspired oxygen of 
less than 1%. 
 
The infant breathed the air/CO2 mixture for at least five minutes to allow ventilation 
and ETCO2 to reach a stable state as assessed from the real-time display using the 
Spectra software (Grove Medical, London, UK). That duration is in keeping with the 
time used in previous studies (10). Neither transcutaneous CO2 monitoring nor blood 
gas analysis was performed. The order of administration of the test gases was 
randomised between infants. All measurements were made during quiet sleep as 
determined by Prechtly criteria (14). When arousal occured the measurement was 
stopped until the infant had returned to quiet sleep and then the measurement began 
again.   
 
 
Respiratory flow and gas concentration were acquired and displayed in real time on a 
PC computer running Spectra software (Grove Medical, London, UK) with 100 Hz 
analogue to digital sampling (PCI-MIO-16XE-50, National Instruments, Austin TX). 
Breath by breath data were exported from Spectra software to Microsoft Excel 2011 
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(Microsoft). Minute volume was calculated from the last minute of exposure at each 
level of CO2. CO2 sensitivity was calculated as the gradient of a line of best fit 
through a plot of the minute ventilation at each of the three inspired CO2 levels (0%, 
2% and 4% CO2). CO2 sensitivity was expressed as ml/kg/min/% CO2, that is the 
change in minute volume per 1% change in the inspired CO2. 
 
Polysomnography 
Polysomnography was performed at the initial study to determine whether the infant 
was having apnoeas. A commercially available Alice 4 sleep study unit (Profile Vio-
systems, Bognor Regis, UK), the Alice 5 firmware upgrade was used.  Abdominal and 
thoracic movements were assessed using stretch sensitive piezo-electric respiratory 
bands. Oral and nasal airflow were measured using the analogue output of the 
pneumotachograph described above. An electrocardiogram was recorded using single 
use bipolar electrodes. Two activity meters were attached one to an arm and the other 
to a leg to record limb movements. Oxygen saturation was continuously monitored 
using a pulse oximeter (Masimo rainbow SET Pulse Oximetry).  The data were 
incorporated into the Alice sleep system using an auxiliary input. 
The Alice sleep system was connected to a PC which was used to display the 
recording in real time and store data. The infant was monitored by video camera 
throughout the study with recordings stored on the PC. These recordings were used to 
assess sleep state and evaluate for artefacts, such as awakenings or handling of the 
infant.  Apnoeas were defined as cessation of respiratory airflow of five seconds in 
duration (15). This definition has been used in the preterm population (16) and 
ensures a sensitive assessment of respiratory pauses that may not be detected by other 
definitions (17). 
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They were classified as obstructive if there was no airflow despite chest and 
abdominal wall movements; central if there was no nasal airflow and an absence of 
chest and abdominal wall movements and mixed if there was a combination of central 
and obstructive apneas.  For each apnoea associated changes in heart rate and oxygen 
saturations were recorded. The apnoea index (the frequency of apneas per hour) was 
calculated.  
 
Caffeine administration 
The decision to treat with caffeine was made by the lead clinician without knowledge 
of the results of the polysomnography or hypercarbic challenge. The criteria for 
treatment with caffeine was apnoea lasting more than twenty seconds or more than ten 
seconds if associated with oxygen desaturation to less than 90% or bradycardia as 
demonstrated by routine clinical monitoring (18). A loading dose of 20mg/kg caffeine 
citrate was administered intravenously, followed by maintenance dose of 10mg/kg 
every 24 hours given either intravenously or enterally. Caffeine therapy was 
discontinued at 34 weeks corrected gestational age, or earlier if the infant had been 
without apnoeas for at least one week. 
 
Data collection 
Birth weight, gestational age at birth and maternal age were recorded. Infants were 
considered to have been exposed to antenatal corticosteroids if at least one dose of 
corticosteroids was given to their mother 24 hours prior to delivery. A diagnosis of 
chorioamnionitis was made if the diagnosis was documented in the obstetric records 
or if the mother had received parenteral antibiotics because of clinical features of 
chorioamnionitis (fever, fetal tachycardia or offensive liquor).  At each study, the 
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current weight, corrected gestational age and postnatal age and caffeine treatment 
were documented from the medical records. 
 
Statistical analysis 
Results were visually assessed for normal distribution using histograms and normality 
plots and shown to be normally distributed. Hence differences in outcomes were 
assessed for statistical significance using Fisher’s exact test or the student t-test as 
appropriate. Comparison of results of the longitudinal measurements of infants  
receiving  or not receiving caffeine were performed using a  paired t-test. 
Linear mixed models with fixed effects were developed to account for repeated 
measures, with carbon dioxide sensitivity as the dependent variable. Corrected 
gestational age was entered as a covariate, when determining the effect of corrected 
gestational age on CO2 sensitivity, with caffeine as a factor to determine the 
additional effect of caffeine on CO2 sensitivity.  
 
Differences in results of the initial challenge between those who that went on to 
require treatment with caffeine and those that did not were assessed using regression 
analysis. Adjustment was made for birthweight and gestational age by fitting those 
variables as covariates. Adjusted means are marginal estimates for the dependent 
variable derived from the regression model at the mean value of the covariates: birth 
weight and gestational age. 
Analyses were conducted using SPSS 22 (IBM). 
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SAMPLE SIZE 
A sample size of two groups of 15 would allow detection of a two-sided difference 
between the caffeine and non treated infants of a difference equivalent to one standard 
deviation to be detected by 90% power. That difference had been detected in the 
ventilatory response to added dead space (primarily a hypercarbic challenge) between 
newborns of smoking and non-smoking mothers (19). 
 
RESULTS 
 
Twenty-six infants born at a median gestation of 32 (range 31-33) weeks and a 
median birth weight 1590 (range 840 – 2200) gms were recruited into the study.  
They were first studied at a median 22 (range 6-69) hours after birth. Ninety-two 
studies, each comprising exposure to the three levels of CO2, were performed with a 
median of 4 (range 1-6) studies per infant.  Fourteen infants developed significant 
apnoea and were treated with caffeine (table 1).   The infants who went on to develop 
significant apnoea were significantly lower birth weight (p=0.03) (Table 1).  At the 
initial study, there was no difference in the apnoea index between those infants that 
went on to develop significant apnoea and those that did not (Table 2). CO2 sensitivity 
was significantly higher following caffeine administration (n=14; mean difference 
41ml/kg/min/% CO2 95% CI 26-57; p<0.001) the measurements were made one week 
apart (Figure 1).  Baseline minute volume while breathing air did not differ 
significantly between the two measurements. (Figure 2) 
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CO2 sensitivity was significantly lower after discontinuing caffeine therapy (n=11; 
mean difference 15 ml/kg/min/%CO2 95% CI 1-29; p=0.036) (Figure 3).   The 
measurements were made one week apart.   
 
A linear mixed model of results from infants who did not receive caffeine (n=12) 
demonstrated that increased corrected gestational age resulted in an increase in carbon 
dioxide sensitivity. A one week increase in corrected gestational age correlated with 
an increase in carbon dioxide sensitivity of 9.5ml/kg/min/%CO2 (95% CI: 4.3-14.6; 
p<0.001). When all the infants were included (n=26) in the analysis and caffeine 
introduced as a factor, corrected gestational age and caffeine both significantly 
contributed to a linear mixed model for CO2 sensitivity. The estimated effect of 
corrected gestational age was an increase of 10.0ml/kg/min/%CO2 (95% CI: 5.4-14.5; 
p<0.001) per week. The estimated marginal mean effect of caffeine therapy on CO2 
sensitivity at 33 weeks of gestation was 15.3 ml/kg/min/%CO2; (95% CI: 1-30; 
p=0.042).  
 
Infants who subsequently developed significant apnoea had significantly lower birth 
weights (p=0.03) and a trend towards lower gestational ages (p=0.06) and lower 
carbon dioxide sensitivities (p=0.065) (Tables 1 and 2). After controlling for the 
effect of corrected gestational age and birth weight, carbon dioxide sensitivity at 
initial study was significantly lower in those infants that went on to develop apnoea 
requiring treatment with caffeine compared to those that did not (Table 2). 
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DISCUSSION 
 
We have demonstrated that caffeine administration was associated with an increase in 
the ventilatory response to hypercarbia in prematurely born infants and that the effect 
remained significant after controlling for increasing maturity. When caffeine was 
discontinued, CO2 sensitivity significantly decreased, further suggesting that the 
effect was due to caffeine administration per se.  Methylxanthines are 
phosphodiesterase inhibitors and, at therapeutic concentrations, are non-specific 
adenosine receptor antagonists. Adenosine receptors are expressed throughout the 
brain stem respiratory centres. There are several subtypes, blockade of which have 
varying effects on respiratory control (20-22). Adenosine A2A receptors play a role in 
the development of late hypoxic ventilatory depression, while A1 receptors contribute 
to cardiorespiratory control during normoxia (23). The role of these receptors changes 
with development.  
 
The response to the initial hypercarbic challenge was significantly weaker in those 
who went on to develop significant apnoea than in those that did not.  Those findings 
are consistent with the reports that a weaker response to hypercarbia was found in 
infants with significant apnoea (3).  Furthermore, Durand et al. compared eight 
preterm infants with at least three episodes a day of apnoea lasting more than 20 
seconds to nine preterm infants without apnoea and reported reduced baseline 
ventilation and CO2 sensitivity in those with apnoea (24). Apnoea resulting in chronic 
intermittent hypoxia, however, may modulate the subsequent ventilator response to 
hypercapnoea (25).  Exposure of neonatal piglets to intermittent hypercapnia and 
hypoxia reduced the subsequent ventilatory response to hypercapnia (26). Two 
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studies, however, in rat pups using several different regimes of hypercapnic or 
normocapnic hypoxia failed to demonstrate a significant effect on the subsequent 
ventilatory response to hypercapnia (27, 28). Millstrom exposed newborn rat pups to 
regimes of intermittent hypercapnic and hypoxia (6% CO2/10% O2), or intermittent 
hypercapnic and hypoxia alternating with hyperoxia (30% O2), five times an hour 
over the first two weeks after birth. Neither regime had any subsequent effect on the 
ventilatory response to hypercarbia (27). Peng used a shorter duration of intermittent 
hypoxia (15 seconds of 5% O2, nine times an hour for eight hours a day during the 
first ten days after birth in newborn rats and again showed no significant difference in 
the their hypercapnic response compared to non-exposed controls (28).  Importantly, 
our study has suggested that a reduced carbon dioxide sensitivity in infants may 
precede the development of significant apnoea and is, therefore, more likely to be a 
contributive factor rather than a result of recurrent apnoea induced episodes of 
hypercarbia and hypoxia. Whether antenatal episodes of hypercarbia may contribute 
is unclear. Those infants that went on to develop significant apnoea were significantly 
more likely to be SGA. Poor growth may reflect impairment of placental blood flow. 
Therefore,  exposure to periods of intermittent hypoxia antenatally could potentially 
contribute to an impairment of CO2 sensitivity.  
 
This study has strengths and some limitations. A strength of our study is that we 
undertook longitudinal measurements, including infants who did not require caffeine 
treatment. Hence, we have been able to control for the maturational effect on the 
ventilatory response to hypercapnia. Our study required recruitment of infants born 
sufficiently prematurely that they were likely to develop apnoea, but did not require 
respiratory support. This, then, was a highly selective group. Unfortunately we did not 
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recruit the target number from the sample size calculation.  Nevertheless, we were 
able to demonstrate significant differences between groups and given the numbers 
recruited we were able to detect differences with 79% power. We did not measure 
caffeine levels. Absorption and metabolism of caffeine is variable in premature 
infants, and therefore may have introduced heterogeneity into the response to caffeine 
therapy. Nonetheless, the effect of caffeine on CO2 sensitivity remained significant. 
  
In conclusion, caffeine administration was associated with an increase in the 
ventilatory response to hypercarbia.  In addition, carbon dioxide sensitivity assessed 
soon after birth was significantly lower in those infants who subsequently required 
treatment with caffeine for apnoea.  
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FIGURE LEGENDS 
 
Figure 1:  Box plot showing carbon dioxide sensitivity before and after 
administration of caffeine.  Box plot shows median and interquartile 
range. Whiskers extend to 1.5 times the interquartile range. Data points 
beyond the interquartile range are marked as outliers. 
Figure 2:  Boxplot showing minute volume while breathing air before caffeine 
therapy was initiated and one week later. Box plot shows median and 
interquartile range. Whiskers extend to 1.5 times the interquartile 
range. Data points beyond the interquartile range are marked as 
outliers. 
 
 
Figure 3:  Boxplot showing carbon dioxide sensitivity while receiving caffeine 
therapy and carbon dioxide sensitivity at the following measurement 
one week later, following cessation of caffeine therapy.  Box plot 
shows median and interquartile range. Whiskers extend to 1.5 times 
the interquartile range. Data points beyond the interquartile range are 
marked as outliers. 
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Table 1: Demographics of study population according to the development of 
significant apnoea.  
Data are presented as mean (standard deviation) if normally distributed; median 
(range); or n 
 
  
No significant 
apnoea 
Significant 
apnoea 
p-value 
n 12  14    
Birthweight (g) 1730 (340) 1450 (290) 0.03 
Gestational age (weeks) 32.7 (0.5) 32.2(0.7) 0.06 
Maternal age (years) 32 (7) 30 (6) 0.45 
Antenatal steroids 10 13 0.58 
Chorioamnionitis 1 3 0.60 
Caesarean section 10 10 0.65 
Sex (F) 6 5 0.69 
Birth weight <10th centile 3 6 0.43 
Singleton 10 9 0.39 
Apgar at 5 minutes 10 (9-10) 9 (8-10) 0.37 
Supplementary oxygen >12 
hours 
7 7 0.71 
Positive pressure support >12 
hours 
3 5 0.68 
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Table 2: Results of the initial study, grouped according to significant apnoea status  
Data are presented as mean (SD) 
* Denotes marginal means adjusted for birth weight and corrected gestational 
age 
 
No significant 
apnoea  
Significant 
apnoea  
p-value 
n 12 14 
 
Baseline minute volume (ml/kg/min) 
   mean (SD) unadjusted 431 (91) 426 (165) 0.92 
mean (95% CI) adjusted* 446 (356-537) 413 (330-496) 0.61 
    
Baseline end-tidal CO2 (%) 
   mean (SD) unadjusted 4.1 (0.7) 4.4 (0.8) 0.22 
mean (95% CI) adjusted* 4.1 (3.6-4.6) 4.4 (4.0-4.9) 0.36 
    
Apnoea index (events/hr) 
   mean (SD) unadjusted 3.8 (3.6) 3.1 (2.4) 0.61 
mean (95% CI) adjusted* 4.1 (1.7-6.5) 2.9 (0.4-5.4) 0.47 
    
CO2 sensitivity (ml/kg/min/%CO2) 
   mean (SD) unadjusted 34 (15) 13 (36) 0.07 
mean (95% CI) adjusted* 38 (19-57) 9 (-8-27) 0.04 
 
 
 
 
 
 
 
 



